Maria Ilma Araujo

Maria Ilma Araujo

Auto-generated profile, based on publicly available information

Maria Ilma Araujo

Serviço de Imunologia, Universidade Federal da Bahia (UFBA), 40110-160 Salvador, BA, Brazil

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
LCLuciana S Cardoso
Luciana S Cardoso
MAMaria Ilma Araujo
Maria Ilma Araujo
AGAlfredo M Góes
Alfredo M Góes
LPLucila G Pacífico
Lucila G Pacífico
RORicardo Riccio Oliveira
Ricardo Riccio Oliveira
Sergio Costa OliveiraSergio Costa Oliveira
Sergio Costa Oliveira
Recombinant proteins expressed in Escherichia coli vectors are generally contaminated with endotoxin. In this study, we evaluated the ability of Polymyxin B to neutralize the effect of LPS present as contaminant on Schistosoma mansoni recombinant proteins produced in E. coli in inducing TNF-α and IL-10. Peripheral blood mononuclear cells from individuals chronically infected with S. mansoni were stimulated in vitro with recombinant Sm22.6, Sm14 and P24 antigens (10 μg/mL) in the presence of Polymyxin B (10 μg/mL). The levels of cytokines were measured using ELISA. There was greater than 90 % reduction (p < 0.05) in the levels of TNF-α and IL-10 when Polymyxin B was added to the cultures stimulated with LPS. In cultures stimulated with S. mansoni recombinant proteins in the presence of Polymyxin B, a reduction in the levels of TNF-α and IL-10 was also observed. However, the percentage of reduction was lower when compared to the cultures stimulated with LPS, probably because these proteins are able to induce the production of these cytokines by themselves. This study showed that Polymyxin B was able to neutralize the effect of endotoxin, as contaminant in S. mansoni recombinant antigens produced in E. coli, in inducing TNF-α and IL-10 production.

2 February 2010 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
LCL. S. Cardoso
L. S. Cardoso
SOS. C. Oliveira
S. C. Oliveira
AGA. M. Góes
A. M. Góes
RORicardo Riccio Oliveira
Ricardo Riccio Oliveira
LPL. G. Pacífico
L. G. Pacífico
MAM I Araujo
M I Araujo
Schistosoma mansoni infection has been associated with protection against allergies. The mechanisms underlying this association may involve regulatory cells and cytokines. We evaluated the immune response induced by the S. mansoni antigens Sm22·6, PIII and Sm29 in a murine model of ovalbumin (OVA)-induced airway inflammation. BALB/c mice were sensitized with subcutaneously injected OVA-alum and challenged with aerolized OVA. Mice were given three doses of the different S. mansoni antigens. Lung histopathology, cellularity of bronchoalveolar lavage (BAL) and eosinophil peroxidase activity in lung were evaluated. Immunoglobulin (Ig)E levels in serum and cytokines in BAL were also measured. Additionally, we evaluated the frequency of CD4+forkhead box P3 (FoxP3)+ T cells in cultures stimulated with OVA and the expression of interleukin (IL)-10 by these cells. The number of total cells and eosinophils in BAL and the levels of OVA-specific IgE were reduced in the immunized mice. Also, the levels of IL-4 and IL-5 in the BAL of mice immunized with PIII and Sm22·6 were decreased, while the levels of IL-10 were higher in mice immunized with Sm22·6 compared to the non-immunized mice. The frequency of CD4+FoxP3+ T cells was higher in the groups of mice who received Sm22·6, Sm29 and PIII, being the expression of IL-10 by these cells only higher in mice immunized with Sm22·6. We concluded that the S. mansoni antigens used in this study are able to down-modulate allergic inflammatory mediators in a murine model of airway inflammation and that the CD4+FoxP3+ T cells, even in the absence of IL-10 expression, might play an important role in this process.

1 June 2013 in Neuroimmunomodulation
Verified
Journal Article
Open access
LLLuciane Mota Lima
Luciane Mota Lima
SSSilvane Braga Santos
Silvane Braga Santos
RORicardo Riccio Oliveira
Ricardo Riccio Oliveira
LCLuciana Santos Cardoso
Luciana Santos Cardoso
Sergio Costa OliveiraSergio Costa Oliveira
Sergio Costa Oliveira
MAMaria Ilma Araújo
Maria Ilma Araújo
Human T cell lymphotropic virus type 1 (HTLV-1) is the causal agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). While the immune response to HTLV-1 infection is polarized to the Th1-type, chronic helminth infections drive the Th2- and T regulatory-type, and are able to downregulate the inflammatory response in some autoimmune diseases. Objective: To evaluate whether Schistosoma spp. antigens alter the in vitro cytokine response in HTLV-1 infection. Methods: The recombinant Schistosoma antigens Sm29 and ShTSP2 (tetraspanin) and PIII, a fraction of the Schistosoma mansoni adult worm antigen were added to peripheral blood mononuclear cell (PBMC) cultures of HTLV-1-infected individuals and the levels of interferon (IFN)-γ and interleukin (IL)-10 in the supernatants were measured using the ELISA sandwich technique. Results: Compared to the levels of cytokine in nonstimulated cultures, the levels of IFN-γ were reduced in 50, 47 and 50% of patients by the presence of Sm29, ShTsp2 and PIII, respectively. The downregulation of IFN-γ production in the presence of Sm29 antigen was observed mainly in subjects who had lower basal levels of this cytokine. The levels of IL-10, however, increased by the addition of the three antigens in the cultures in 74, 62 and 44% of individuals, respectively. In addition, there was a decrease in the ratio of IFN-γ/IL-10 levels in cultures stimulated with Sm29 and ShTSP2 when compared to nonstimulated ones. Conclusions: The Schistosoma spp. antigens used in this study were able to downmodulate IFN-γ production in vitro in HTLV-1 infection. This may be associated with the increased levels of IL-10 induced by the antigens.

1 June 2010 in Inflammation & Allergy - Drug Targets
Verified
Journal Article
Closed access
PDF file
MAMaria I. Araujo
Maria I. Araujo
RCRegis A. Campos
Regis A. Campos
LCLuciana S. Cardoso
Luciana S. Cardoso
SOSergio C. Oliveira
Sergio C. Oliveira
ECEdgar M. Carvalho
Edgar M. Carvalho
Studies of the molecular mechanisms associated with allergic diseases have lead to a better understanding of the complex processes that underlie their pathogenesis. These mechanisms involve Th2- and Th1-type cells and also some recently described cytokines, such as IL-25 and IL-33. Regulatory mechanisms of allergic inflammation have also been identified. For instance, IL-10, a cytokine produced by many cell types, promotes a decrease in IgE production, and inhibits the release of histamine and other inflammatory mediators by mast cells. Recently, a variety of regulatory cells have been discovered, which, either by direct contact or through the production of IL-10 and/or TGF-β, can inhibit the allergic inflammatory response. IL-10 is produced in high levels by cells of helminth-infected individuals. There is some evidence that such infections protect against the development of allergic diseases. In asthmatic individuals living in endemic areas of schistosomiasis, it has been shown in in vitro studies that there is a modulation of the Th2 response, both by mechanisms involving IL-10, which is produced mainly by monocytes and CD4+CD25+ T regulatory cells, and also by the expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) in CD4+ T cells. Studies using parasite antigens to induce the modulation of allergic inflammatory response are being conducted by several groups of researchers and represent new perspectives for the treatment of allergic diseases.

1 January 2012 in Journal of Parasitology Research
Verified
Journal Article
Open access
PDF file
MAMaria Cecilia F. Almeida
Maria Cecilia F. Almeida
GLGivaneide S. Lima
Givaneide S. Lima
LCLuciana S. Cardoso
Luciana S. Cardoso
RSRobson P. de Souza
Robson P. de Souza
RCRégis A. Campos
Régis A. Campos
MAMaria Ilma Araujo
Maria Ilma Araujo
This is a prospective, double-blinded, and placebo-controlled trial evaluating the influence of antihelminthic treatments on asthma severity in individuals living in an endemic area of schistosomiasis. Patients from group 1 received placebo of Albendazole or of Praziquantel and from group 2 received Albendazole and Praziquantel. Asthma severity was assessed by clinical scores and by pulmonary function test. There was no significant difference in the asthma scores from D0 to D1–D7 after Albendazole or Praziquantel and from D0 to D30–90 after Albendazole or Praziquantel in both, group 1 and 2. It was observed, however, a clinical worsening of the overall studied population after 6 months and 12 months of antihelminthic treatments. Additionally, we observed increased frequency of forced expiratory volume in 1 second (FEV1)<80% on 12 and 18 months after treatment. The worsening of asthma severity after repeated antihelminthic treatments is consistent with the hypothesis of the protective role conferred by helminths in atopic diseases.

20 September 2011 in Drug Development Research
Verified
Journal Article
Open access
PDF file
LCL.S. Cardoso
L.S. Cardoso
Sergio Costa OliveiraSergio Costa Oliveira
Sergio Costa Oliveira
RSR.P. Souza
R.P. Souza
AGA.M. Góes
A.M. Góes
RORicardo Riccio Oliveira
Ricardo Riccio Oliveira
MAM.I. Araujo
M.I. Araujo
Schistosoma mansoni infection is associated with a low prevalence of asthma and a less severe form of the disease. The mechanisms underlying this association may include the production of regulatory cells and cytokines. The aim of this study was to evaluate the immune response induced by the S. mansoni antigens, Sm22.6, PIII, and Sm29 and their ability to suppress allergen‐specific IL‐5 production by peripheral blood mononuclear cells (PBMC) from asthmatic individuals. PBMCs were stimulated in vitro with S. mansoni antigens in the presence or absence of antigen‐1 of the mite Dermatophagoides pteronyssinus (Der p1). Cytokines were measured in PBMC supernatants by enzyme‐linked immunosorbent assay (ELISA), and the phenotype of cells producing IL‐10 was assessed using flow cytometry. High production of S. mansoni antigen‐specific IL‐10 was observed not only in cells of S. mansoni‐infected individuals, but also in cells of noninfected asthmatic individuals. In the former group, the main cellular sources of IL‐10 were CD4+ CD25+, and CD14+ cells. The levels of IFN‐γ, IL‐5, and IL‐13 in the noninfected asthmatic group were ∼100 pg/ml in response to the antigens. Moreover, when S. mansoni antigens were added to cultures stimulated with Der p1, levels of IL‐10 were increased (Der p1 = 234 ± 118; Der p1 + Sm22.6 = 1189 ± 595; Derp1 + PIII = 799 ± 331; Derp1 + Sm29 = 652 ± 288 pg/ml) with reduced levels of IL‐5 (Der p1 = 286 ± 219; Der p1 + Sm22.6 = 93 ± 153; Derp1 + PIII = 132 ± 188; Derp1 + Sm29 = 96 ± 86 pg/ml). The S. mansoni antigens evaluated in the present study induced the production of the regulatory cytokine IL‐10 and down‐modulated the Th2 immune response that participates in the pathology of asthma. Drug Dev Res 72:538–548, 2011.